Teva’s Weltruza was “developed with the patient in mind from day one,” says Chris Fox, Executive VP, as the company advances ...
以色列藥廠Teva於美國時間10月9日宣布，旗下長效注射劑Weltruza獲美國食品藥物管理局（FDA）核准，用於成人思覺失調症，預計未來數週在美國上市，為患者提供新的治療選擇。這款藥採用既有抗精神病成分olanzapine，每月皮下注射一 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results